| 0.42 0.01 (2.44%) | 09-15 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.59  |
1-year : | 0.7 |
| Resists | First : | 0.5 |
Second : | 0.6 |
| Pivot price | 0.39 |
|||
| Supports | First : | 0.36 | Second : | 0.29 |
| MAs | MA(5) : | 0.4 |
MA(20) : | 0.4 |
| MA(100) : | 0.41 |
MA(250) : | 0.81 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 74.3 |
D(3) : | 60.4 |
| RSI | RSI(14): 49.6 |
|||
| 52-week | High : | 2.75 | Low : | 0.16 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ MGRX ] has closed below upper band by 8.7%. Bollinger Bands are 73.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.43 - 0.43 | 0.43 - 0.43 |
| Low: | 0.4 - 0.4 | 0.4 - 0.4 |
| Close: | 0.42 - 0.42 | 0.42 - 0.42 |
Mangoceuticals, Inc. dedicates its operations to the creation, promotion, and distribution of a variety of health and wellness products and services specifically designed for men. These offerings are primarily delivered through a telemedicine platform. The company's product line includes treatments for erectile dysfunction, marketed under the 'Mango' brand. Consumers can purchase these items directly from its official online portal, mangorx.com. Established in 2021, Mangoceuticals, Inc. is headquartered in Dallas, Texas, and operates as an affiliate of Cohen Enterprises, Inc.
Fri, 21 Aug 2026
Mangoceuticals Terminates Nuclea Energy Business Combination After $15 Million PIPE Not Secured - tradingview.com
Thu, 13 Aug 2026
Nuclea’s planned Moltex deal could add 80 nuclear patents - Stock Titan
Thu, 13 Aug 2026
Mangoceuticals (MGRX) Q2 2026 loss shrinks while cash and revenue fall - Stock Titan
Tue, 04 Aug 2026
Mangoceuticals Granted 180-Day Extension by Nasdaq to - GlobeNewswire
Fri, 31 Jul 2026
Friday's pre-market session: top gainers and losers - ChartMill
Fri, 31 Jul 2026
MGRX surges after Nuclea Energy reverse-merger deal reshapes company story - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Healthcare Information Services
|
|
| Shares Out | 0 (M) |
| Shares Float | 22 (M) |
| Held by Insiders | 1.687e+007 (%) |
| Held by Institutions | 7.9 (%) |
| Shares Short | 208 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.237e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 502.4 % |
| Return on Equity (ttm) | -48 % |
| Qtrly Rev. Growth | 315230 % |
| Gross Profit (p.s.) | -18.05 |
| Sales Per Share | -54.24 |
| EBITDA (p.s.) | 103486 |
| Qtrly Earnings Growth | -1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 1.81e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|